Acri.LISA offers a full range of vision

Article

Bilateral implantation of the Acri.LISA 366D distance-dominant bifocal intraocular lens provides a satisfactory full range of vision.

Bilateral implantation of the Acri.LISA 366D distance-dominant bifocal intraocular lens (IOL) provides a satisfactory full range of vision, according to the results of a study published in the November issue of the Journal of Cataract and Refractive Surgery.

José Alfonso and colleagues from the Fernández-Vega Ophthalmological Institute, Oviedo, Spain bilaterally implanted the Acri.LISA 366D IOL in 81 patients. Monocular and binocular best corrected visual acuity and best distance corrected near visual acuity, binocular best distance corrected intermediate visual acuity and distance contrast sensitivity under photopic and mesopic conditions were determined.

At three months follow-up, the mean binocular best corrected distance visual acuity was 0.048±0.111 logMAR and the mean binocular best distance corrected near acuity was 0.012±0.0084 logMAR. The mean binocular best distance corrected intermediate acuity changed significantly as a function of the distance of the test from 0.012±0.084 logMAR at 33 cm to 0.265±0.099 logMAR at 70 cm (p<0.01). Contrast sensitivity was within normal limits under photopic and mesopic conditions.

These results demonstrate that the Acri.LISA 366D IOL offers a good full range of vision.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.